Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: An updated meta-analysis

Yonsei Medical Journal

Volumn 54, Issue 6, 2013, Pages 1384-1393

  Zhu, Ning ^a   Gong, Yi ^a   He, Jian ^a   Xia, Jingwen ^a   Chen, Xiaodong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

C677T; Lung cancer; MTHFR; Platinum based chemotherapy; Polymorphism

Indexed keywords

5, 10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); PLATINUM; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; GENETIC HETEROGENEITY; GENETIC MARKER; HOMOZYGOTE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; PROTEIN POLYMORPHISM; PUBLISHING;

C677T; LUNG CANCER; MTHFR; PLATINUM-BASED CHEMOTHERAPY; POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLATINUM; POLYMORPHISM, GENETIC;

EID: 84886573431     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.6.1384     Document Type: Article

References (47)

1. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3: 912-20.
2. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004;208:1-33.
3. Vaissière T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 2009;69:243-52.
4. Männistö S, Smith-Warner SA, Spiegelman D, Albanes D, Anderson K, van den Brandt PA, et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomarkers Prev 2004;13:40-8.
5. Jatoi A, Daly BD, Kramer G, Mason JB. Folate status among patients with non-small cell lung cancer: a case-control study. J Surg Oncol 2001;77:247-52.
6. Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 1999;10:66-88.
7. Voorrips LE, Goldbohm RA, Brants HA, van Poppel GA, Sturmans F, Hermus RJ, et al. A prospective cohort study on antioxidant and folate intake and male lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:357-65.
8. Shimamoto T, Ohyashiki JH, Hirano T, Kato H, Ohyashiki K. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. Oncol Rep 2004;12:389-95.
9. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004;96:134-44.
10. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 2001;10: 397-401.
11. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5:226-43.
12. Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y. Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population. BMC Cancer 2011;11:459.
13. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics 2011;12:797-808.
14. Siemianowicz K, Gminski J, Garczorz W, Slabiak N, Goss M, Machalski M, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. Oncol Rep 2003;10:1341-4.
15. Suzuki T, Matsuo K, Hiraki A, Saito T, Sato S, Yatabe Y, et al. Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis 2007;28:1718-25.
16. Liu CS, Tsai CW, Hsia TC, Wang RF, Liu CJ, Hang LW, et al. Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. Cancer Genomics Proteomics 2009;6:325-9.
17. Zhang Y, Chen GQ, Ji Y, Huang B, Shen WS, Deng LC, et al. Quantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep 2012;39:6203-11.
18. Alberola V, Sarries C, Rosell R, Taron M, de las Peñas R, Camps C, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin Lung Cancer 2004;5:360-5.
19. Shi M, Gao C, Wu J, Feng J, Cao H, Lu J, et al. [Genetic polymorphisms in methylenetetrahydrofolate reductase and clinical response to chemotherapy in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2006;9:519-24.
20. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
22. Takehara A, Kawakami K, Ohta N, Oyama K, Ota Y, Oda M, et al. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res 2005;25:4455-61.
23. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol 2007;18:1230-42.
24. Zhou QF, Chen SQ, Ma L, Li ZB, Li WD, Chen WS, et al. The associations of MTHFR polymorphism and lung cancer risk (chinese). Chin J Cancer Res Prev Treat 2006;8:572-4.
25. Jin C, Zhang YH, Peng MF, Li WD, Ma L, Chen WS. The association between MTHFR polymorphism and lung cancer (chinese). Chin J Cancer Prev Treat 2007;12:888-91.
26. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated nonsmall-cell lung cancer patients. Ann Oncol 2006;17:668-75.
27. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, et al. Prognostic significance of folate metabolism polymorphisms for lung cancer. Br J Cancer 2007;97:247-52.
28. Heijmans BT, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG, Kromhout D, et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 2003;63:1249-53.
29. Jeng YL, Wu MH, Huang HB, Lin WY, You SL, Chu TY, et al. The methylenetetrahydrofolate reductase 677C-->T polymorphism and lung cancer risk in a Chinese population. Anticancer Res 2003;23:5149-52.
30. Shen M, Rothman N, Berndt SI, He X, Yeager M, Welch R, et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer 2005;49:299-309.
31. Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, et al. Sex differences in risk of lung cancer associated with methylenetetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers Prev 2005;14:1477-84.
32. Zhang XM, Miao XP, Tan W, Qu SN, Sun T, Zhou YF, et al. [Association between genetic polymorphisms in methylentetrahydrofolate reductase and risk of lung cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005;27:700-3.
33. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007;28:1287-93.
34. Hung RJ, Hashibe M, McKay J, Gaborieau V, Szeszenia-Dabrowska N, Zaridze D, et al. Folate-related genes and the risk of tobacco-related cancers in Central Europe. Carcinogenesis 2007;28: 1334-40.
35. Liu H, Jin G, Wang H, Wu W, Liu Y, Qian J, et al. Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. Lung Cancer 2008;61:21-9.
36. Arslan S, Karadayi S, Yildirim ME, Ozdemir O, Akkurt I. The association between methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk. Mol Biol Rep 2011;38:991-6.
37. Cui LH, Shin MH, Kim HN, Song HR, Piao JM, Kweon SS, et al. Methylenetetrahydrofolate reductase C677T polymorphism in patients with lung cancer in a Korean population. BMC Med Genet 2011;12:28.
38. Cheng Z, Wang W, Song YN, Xia J, Kang Y, Dai LL, et al. The relationship between MTHFR C677T polymorphism and lung cancer risk (chinese). Chin J Tuberc Respir Dis 2011;34:57-8.
39. Jin C, Zhang YH, Peng MF, Li WD, Ma L, Chen WS. The relationship between MTHFR C677T and A1298C polymorphism and lung cancer risk (chinese). Lin Chuang Zhong Liu Xue Za Zhi 2007;9:671-5.
40. Yang XX, Li FX, Yi JP, Li X, Sun JZ, Hu NY. The relationship between MTHFR C677T polymorphism and gastric cancer, colon cancer or lung cancer risk (chinese). Guangdong Med J 2010;31: 2375-8.
41. Tong SY, Kim MK, Lee JK, Lee JM, Choi SW, Friso S, et al. Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks of cervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitamin B12. Cancer Causes Control 2011;22:63-72.
42. Xuan C, Bai XY, Gao G, Yang Q, He GW. Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res 2011;42:677-85.
43. Yan J, Yin M, Dreyer ZE, Scheurer ME, Kamdar K, Wei Q, et al. A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2012;58:513-8.
44. Jokič M, Brčič-Kostič K, Stefulj J, Catela Ivkovič T, Božo L, Gamulin M, et al. Association of MTHFR, MTR, MTRR, RFC1, and DHFR gene polymorphisms with susceptibility to sporadic colon cancer. DNA Cell Biol 2011;30:771-6.
45. Mao R, Fan Y, Jin Y, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. J Hum Genet 2008;53:340-8.
46. Boccia S, Boffetta P, Brennan P, Ricciardi G, Gianfagna F, Matsuo K, et al. Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett 2009;273:55-61.
47. Hou XH, Huang YM, Mi YY. Methylenetetrahydrofolate reductase gene C677T polymorphism and lung cancer: an updated meta-analysis. Asian Pac J Cancer Prev 2012;13:2025-9.